Novartis
Discount fails to sway NICE on Gilenya
December 1, 2011Sales and Marketing NICE, Novartis, gilenya
NICE has once again rejected Novartis’ multiple sclerosis pill Gilenya despite the firm offering a patient access scheme. In its …
Lucentis not backed by NICE for new licence
November 24, 2011Sales and Marketing Lucentis, NICE, Novartis, Ozurdex
NICE has not recommended Novartis’ eye disease drug Lucentis due to ‘gaps and uncertainties’ in the manufacturer’s submission. In draft …
Lucentis rival gains US approval
November 22, 2011Research and Development, Sales and Marketing Bayer, Eylea, Lucentis, Novartis, Regeneron, Roche
A rival to Roche and Novartis’ drug Lucentis has received FDA approval for a common form of eye disease. Eylea …
Novartis workers stage flash strike over job cuts
November 21, 2011Manufacturing and Production Novartis, Switzerland, job cuts
Workers at Novartis’ Nyon facility in Switzerland carried out a strike to protest the closure of the plant, but called …
Timothy Wright appointed as global head of development at Novartis Pharmaceuticals
November 9, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis
Novartis has appointed Dr Timothy Wright as the new global head of development of its pharmaceuticals business, effective immediately. Dr …
Carsten Schroeder appointed interim president of Novartis Diagnostics
October 31, 2011Sales and Marketing Novartis
Schroeder was previously vice president of Novartis Diagnostics for commercial operations in Europe, the Middle East and Africa. He will …
Novartis job cuts protest
October 31, 2011Manufacturing and Production, Sales and Marketing Novartis, job cuts, manufacturing and production
Protesters have been demonstrating outside the home of Novartis chairman Daniel Vasella and in the streets of Basel, Switzerland, in …
Novartis loses global development head to Gates Foundation
September 14, 2011Research and Development Bill and Melinda Gates Foundation, Novartis, appointment
Novartis’ global head of development Trevor Mundel is to leave the company and take a senior position at The Bill …
Everolimus approved to treat rare tumour disease
September 8, 2011Sales and Marketing Novartis, SEGA, Votubia, everolimus
Novartis has gained EU approval for everolimus to be used to treat a rare non-cancerous tumour. Everolimus is already marketed …
Afinitor expands European licence
September 5, 2011Sales and Marketing Afinitor, Novartis, Pancreatic cancer
Novartis’ Afinitor has made further strides in the EU with an approval for use in patients with advanced pancreatic neuroendocrine …
Gilenya rejected by NICE
August 5, 2011Medical Communications, Sales and Marketing MS, NICE, Novartis, gilenya
NICE has not recommended Novartis’ multiple sclerosis drug Gilenya because of its cost and ‘uncertainties over its clinical effectiveness’. Gilenya …
Afinitor poised to realise blockbuster ambitions?
July 25, 2011Sales and Marketing Afinitor, Cancer, Novartis
Novartis’ Afinitor may be set to make good on its blockbuster promise after receiving European backing for its second licence …
Novartis posts double-digit sales and profit growth
July 19, 2011Sales and Marketing Novartis
Novartis had a strong second quarter of the year, with both sales and profit up on the same period in …
NICE decides laser treatment better than Lucentis
July 18, 2011Sales and Marketing Lucentis, NICE, Novartis
Novartis says it is “disappointed” with health watchdog NICE’s decision not to recommend Lucentis for the treatment of eye problems …
Novartis’ Votubia reduces benign brain tumours in SEGA patients
July 11, 2011Research and Development Novartis, SEGA, Votubia, everolimus
Novartis’ novel cancer drug Votubia has reduced the size of SEGA brain tumours in a late-stage trial. Votubia (or everolimus …
Latest content
FibroFind appoints Lee Borthwick as CEO
